Stocks
Nu Skin Enterprises Financial Statements (NUS) |
||||||||||
| Nu Skin Enterprisessmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 04.05.2023 | 02.08.2023 | 02.11.2023 | 15.02.2024 | 09.05.2024 | 09.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 481.5 | 500.3 | 498.8 | 488.6 | 417.3 | 1 905 | |||
| Operating Income, bln rub | 16.1 | 42.5 | -26.4 | 26.1 | 16.0 | 58.2 | ||||
| EBITDA, bln rub | ? | 35.6 | 59.7 | -26.4 | 43.3 | 34.4 | 111.0 | |||
| Net profit, bln rub | ? | 11.4 | 26.9 | -37.0 | 7.28 | -0.533 | -3.31 | |||
| OCF, bln rub | ? | -22.1 | 35.5 | 51.0 | 54.2 | 3.32 | 144.0 | |||
| CAPEX, bln rub | ? | 11.5 | 14.7 | 11.9 | 20.4 | 12.3 | 59.3 | |||
| FCF, bln rub | ? | -33.6 | 20.8 | 39.1 | 33.8 | -8.96 | 84.8 | |||
| Dividend payout, bln rub | 19.4 | 19.5 | 19.5 | 19.3 | 2.98 | 61.2 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 170.5% | 72.4% | 0.00% | 264.6% | 0.00% | -1 847% | ||||
| OPEX, bln rub | 322.0 | 322.2 | 318.6 | 326.4 | 278.1 | 1 245 | ||||
| Cost of production, bln rub | 133.6 | 135.5 | 206.5 | 136.2 | 123.2 | 601.5 | ||||
| R&D, bln rub | 0.000 | 0.000 | 0.000 | 22.6 | 0.000 | 22.6 | ||||
| Interest expenses, bln rub | 1.48 | 0.000 | 0.000 | 1.48 | 7.33 | 8.80 | ||||
| Assets, bln rub | 1 825 | 1 894 | 1 793 | 1 806 | 1 742 | 1 742 | ||||
| Net Assets, bln rub | ? | 893.0 | 895.3 | 822.2 | 822.0 | 810.2 | 810.2 | |||
| Debt, bln rub | 498.9 | 582.2 | 571.1 | 607.3 | 557.4 | 557.4 | ||||
| Cash, bln rub | 246.7 | 252.3 | 250.0 | 267.8 | 221.2 | 221.2 | ||||
| Net debt, bln rub | 252.2 | 329.9 | 321.1 | 339.5 | 336.2 | 336.2 | ||||
| Ordinary share price, rub | 39.3 | 33.2 | 21.2 | 19.4 | 13.8 | 16.9 | ||||
| Number of ordinary shares, mln | 49.6 | 49.9 | 49.9 | 49.4 | 49.5 | 49.5 | ||||
| Market cap, bln rub | 1 952 | 1 658 | 1 058 | 960 | 685 | 835 | ||||
| EV, bln rub | ? | 2 204 | 1 988 | 1 379 | 1 299 | 1 021 | 1 171 | |||
| Book value, bln rub | 622 | 553 | 484 | 486 | 478 | 478 | ||||
| EPS, rub | ? | 0.23 | 0.54 | -0.74 | 0.15 | -0.01 | -0.07 | |||
| FCF/share, rub | -0.68 | 0.42 | 0.78 | 0.68 | -0.18 | 1.71 | ||||
| BV/share, rub | 12.5 | 11.1 | 9.70 | 9.83 | 9.64 | 9.64 | ||||
| EBITDA margin, % | ? | 7.40% | 11.9% | -5.29% | 8.87% | 8.24% | 5.83% | |||
| Net margin, % | ? | 2.36% | 5.38% | -7.41% | 1.49% | -0.13% | -0.17% | |||
| FCF yield, % | ? | 0.93% | 0.12% | 3.60% | 6.27% | 12.4% | 10.1% | |||
| ROE, % | ? | 8.67% | 7.83% | 7.12% | 1.05% | -0.41% | -0.41% | |||
| ROA, % | ? | 4.24% | 3.70% | 3.26% | 0.48% | -0.19% | -0.19% | |||
| P/E | ? | 25.2 | 23.7 | 18.1 | 111.6 | -206.7 | -252.0 | |||
| P/FCF | 107.3 | 839.8 | 27.7 | 16.0 | 8.08 | 9.85 | ||||
| P/S | ? | 0.93 | 0.81 | 0.53 | 0.49 | 0.36 | 0.44 | |||
| P/BV | ? | 3.14 | 3.00 | 2.19 | 1.97 | 1.43 | 1.75 | |||
| EV/EBITDA | ? | 10.5 | 9.96 | 10.4 | 11.6 | 9.20 | 10.6 | |||
| Debt/EBITDA | 1.20 | 1.65 | 2.41 | 3.02 | 3.03 | 3.03 | ||||
| R&D/CAPEX, % | 0.00% | 0.00% | 0.00% | 110.9% | 0.00% | 38.1% | ||||
| CAPEX/Revenue, % | 2.39% | 2.94% | 2.39% | 4.17% | 2.94% | 3.11% | ||||
| Nu Skin Enterprises shareholders | ||||||||||
